Please assess the completion status of the following clinical trial:

Trial Title: Adenosin to Rapidly Reverse Left Ventricle Impairment in Takotsubo Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old~* Evidence of typical anatomical pattern to the left ventriculography (total akinesia of the mid-apical segments with hypercontractility basal segments) associated with the presence of criteria for the diagnosis of Takotsubo syndrome (Table 1)~* signing of informed consent~Exclusion Criteria:~* allergy to adenosine~* known and documented diagnosis of asthma~* pre-existing ischemic heart disease~* presence of arrhythmic complication (AV block grade II type 2 and third degree)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adenosine (Type: EXPERIMENTAL): Patients in this arm will receive systemic infusion of adenosine at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
- Saline solution (Type: PLACEBO_COMPARATOR): Patients in this arm will receive systemic infusion of saline solution at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).